NOVONESIS B UNSP/ADRNVZMY

NOVONESIS B UNSP/ADR (NVZMY): trades by Congress and the executive branch

Every trade in NOVONESIS B UNSP/ADR that a representative, a senator, the President or a senior official disclosed since 2018, newest report first. Each is read from the filer’s periodic transaction report and linked to it.

Latest report Jul 7, 2026 · Source · RSS feed

Trades disclosed
15since 2018
Members
4
Purchases / sales
8 / 7
Typical days to public
32median
Public after 45 days
3of 15 dated trades by Congress

Congress trade alerts · NVZMY · free

Get an email when anyone in Congress trades NOVONESIS B UNSP/ADR

Each new disclosure of a trade in the stock by a representative, a senator, the President or a senior official, with the filing.

An email when a member of Congress or the executive branch files a trade in NVZMY, with the filing. Unsubscribe in one click.

Transactions

Every NVZMY trade disclosed since 2018, newest report first
MemberAssetTypeAmountTrade dateLagPublicFiling
Josh GottheimerD-NJNJ05NVZMYNOVONESIS B UNSP/ADR · JointSell$1K–$15KJun 1, 202636dJul 7PDF
Josh GottheimerD-NJNJ05NVZMYNovozymes A/S · JointBuy$1K–$15KOct 16, 202326dNov 11PDF
Josh GottheimerD-NJNJ05NVZMYNovozymes A/S · JointSell$1K–$15KSep 15, 202330dOct 15PDF
Peter MeijerR-MIMI03NVZMYNovozymes A/SSell$1K–$15KFeb 17, 202127dMar 16PDF
Greg GianforteR-MTMT00NVZMYNovozymes A/S · JointSell$15K–$50KAug 4, 202014dAug 18PDF
Donna ShalalaD-FLFL27NVZMYNovozymes A/SSell$1K–$15KJun 24, 2019308dApr 27PDF
Greg GianforteR-MTMT00NVZMYNovozymes a/S · JointBuy$1K–$15KMar 18, 202020dApr 7PDF
Greg GianforteR-MTMT00NVZMYNovozymes a/S · JointBuy$15K–$50KJan 13, 202032dFeb 14PDF
Greg GianforteR-MTMT00NVZMYNovozymes A/S · JointBuy$50K–$100KOct 11, 201947dNov 27PDF
Greg GianforteR-MTMT00NVZMYNovozymes A/S · JointSell$100K–$250KSep 10, 201940dOct 20PDF
Greg GianforteR-MTMT00NVZMYNovozymes A/S · JointBuy$100K–$250KDec 21, 201833dJan 23PDF
Greg GianforteR-MTMT00NVZMYNovozymes A/S · JointSell$100K–$250KNov 20, 201821dDec 11PDF
Josh GottheimerD-NJNJ05NVZMYNovozymes a/S · JointBuy$1K–$15KOct 11, 201836dNov 16PDF
Josh GottheimerD-NJNJ05NVZMYNovozymes a/S · JointBuy$1K–$15KMar 16, 2018200dOct 2PDF
Greg GianforteR-MTMT00NVZMYNovozymes A/S · JointBuy$100K–$250KMar 20, 20187dMar 27PDF

Members who traded NVZMY

MemberTradesBuysSellsLast tradedLatest report
Greg GianforteR-MTMT00853Aug 4, 2020Aug 18, 2020
Josh GottheimerD-NJNJ05532Jun 1, 2026Jul 7, 2026
Peter MeijerR-MIMI03101Feb 17, 2021Mar 16, 2021
Donna ShalalaD-FLFL27101Jun 24, 2019Apr 27, 2020

Source

Each trade is a line of a periodic transaction report filed under the STOCK Act, read from the report itself and linked to it. Three offices publish them, and all three are read here every hour: the House Clerk for representatives, the Senate Office of Public Records for senators, and the Office of Government Ethics for the President, the Vice President and Senate-confirmed officials (OGE Form 278-T). OGE links some officials’ reports and releases the rest on request; only linked reports are here.

The Act requires a report within 45 days of the trade; the lag counts the days from the trade to the day the report became public. Reports give each amount as a range. Amendments are marked and not counted as late; trades a later report withdrew are left out. The President’s reports and some House reports are scans of paper forms: a scanned value that does not read with certainty is shown as not read, never guessed, and the report is one click away. “Since” is the stock’s move from the trade date’s close to the latest daily close.

The same trades are in the OptimistFi MCP server’s get_congress_trades tool, by filer or by stock, for each chamber: connect it. Every House trade is free to download as CSV or JSON, and every trade here can be followed by RSS: the data.

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.